Carvedilol Prevents Ovariectomy-Induced Myocardial Contractile Dysfunction in Female Rat

Rogerio Faustino Ribeiro Jr.1,*, Felipe F. Potratz1, Brunella M. M. Pavan1, Ludimila Forechi1, Filipe Lugon Moulin Lima1, Jonaina Fiorim1, Aurelia Araujo Fernandes1, Dalton Valentim Vassallo1,2, Ivanita Stefanon1

1 Department of Physiological Sciences, Federal University of Espirito Santo, Vitoria, Brazil, 2 Department of Physiological Sciences, EMESCAM, Vitoria, Brazil

Abstract
Carvedilol has beneficial effects on cardiac function in patients with heart failure but its effect on ovariectomy-induced myocardial contractile dysfunction remains unclear. Estrogen deficiency induces myocardial contractile dysfunction and increases cardiovascular disease risk in postmenopausal women. Our aim was to investigate whether carvedilol, a beta receptor blocker, would prevent ovariectomy-induced myocardial contractile dysfunction. Female rats (8 weeks old) that underwent bilateral ovariectomy were randomly assigned to receive daily treatment with carvedilol (OVX+CAR, 20 mg/kg), placebo (OVX) and SHAM for 58 days. Left ventricle papillary muscle was mounted for isometric tension recordings. The inotropic response to Ca2+ (0.62 to 3.75 mM) and isoproterenol ( Iso 10^-8 to 10^-2 M) were assessed. Expression of calcium handling proteins was measured by western blot analysis. Carvedilol treatment in the OVX animals: prevented weight gain and slight hypertrophy, restored the reduced positive inotropic responses to Ca2+ and isoproterenol, prevented the reduction in SERCA2a expression, abolished the increase in superoxide anion production, normalized the increase in p22phox expression, and decreased serum angiotensin converting enzyme (ACE) activity. This study demonstrated that myocardial contractile dysfunction and SERCA2a down regulation were prevented by carvedilol treatment. Superoxide anion production and NADPH oxidase seem to be involved in this response.

Introduction
Cardiovascular diseases are the leading cause of death in developed countries and are more prevalent in men as compared to premenopausal women [1–4]. Despite aggressive diagnosis and treatment, cardiovascular diseases still remain a major and growing public health problem [5]. It is well known that estrogen is linked to cardiovascular protection in premenopausal women whereas hormone replacement therapy (HRT) may have detrimental effects on cardiovascular function [6–8]. The use of HRT failed to reduce cardiovascular risks and controversies regarding the safety of HRT have drawn attention to new therapies for postmenopausal women [9,10].

Estrogen deficiency plays a role in the contractile activity of the heart [11–13] most likely by decreasing SERCA2a expression and its function, decreasing Ca2+ responsiveness of myofilament activation and increasing phospholamban expression [1,9,14]. The decline in cardiac contractile function is characterized mainly by altered excitation-contraction coupling and impaired myofilament calcium responsiveness [1,15]. Recently we demonstrated that myocardial contractile dysfunction induced by ovariectomy and expression of key Ca2+-handling proteins were prevented by losartan treatment and that AT1 receptor activation is involved in this response [16].

Furthermore, estrogen decreases angiotensin converting enzyme (ACE) activity and the risk of coronary artery disease in women [17]. Recent studies showed that ACE activity appears to be affected by estrogen and the down-stream signaling of the AT1 receptor [18]. The reduction in ACE activity was not due to a direct interaction of estrogen with the enzyme; rather, it seems that estrogen regulates ACE mRNA synthesis at the tissue level [19].

The renin angiotensin system plays an important role in cardiovascular regulation through angiotensin II [20]. Angiotensin II increases NADPH oxidase activity and its expression, thereby increasing reactive oxygen species (ROS), leading to cardiac remodeling and contractile dysfunction [15,20]. Cardiomyocytes are sensitive to oxidative stress and ROS are capable of influencing cellular calcium regulation at several levels, including calcium overload and oxidation of proteins involved in calcium handling such as ryanodine receptor, SERCA2a, Na+-Ca2+ exchanger and phospholamban [21,22]. Besides, ROS also down regulate the expression of the gene responsible for SERCA2a expression, resulting in reduced rates of relaxation/contraction cycling [22,23]. Normalized excitation-contraction coupling is essential to maintain cardiac homeostasis and cardiac function [15,20].
Ribeiro Junior et al. [16] demonstrated that losartan restored the positive inotropic responses to Ca\(^{2+}\) and isoproterenol, prevented the reduction in SERCA2a levels and the increase in phospholamban (PLB) expression, abolished the increase in superoxide anion and normalized the increase in p22\(^{phox}\) expression in isolated papillary muscle from ovariectomized rats.

On the other hand, carvedilol, a beta receptor blocker has been widely used in humans for the treatment of heart failure once it improves symptoms and cardiac performance, with a marked reduction in cardiovascular events after onset of the disease [22–25].

Part of the cardioprotection afforded by carvedilol is due to its antioxidant activity, tenfold greater than any antioxidant such as vitamin E [22] and by the interaction between either the β-1 or β-2 adrenergic and AT1 receptor. Interfering with the signaling of one receptor, i.e. selective β adrenergic receptor blockade inhibits signaling of AT1 receptor, resulting in the inhibition of signaling by the reciprocal, interacting receptor [26]. Carvedilol also prevents ROS-induced decrease in SERCA2a expression [23]. Sarcoplasmatic reticulum Ca\(^{2+}\)-adenosine triphosphatase (SERCA2a) and phospholamban are the major proteins responsible for intracellular calcium homeostasis [9,27–30]. Carvedilol also prevents lipid and protein peroxidation induced by oxygen radicals; decreases oxidative stress and calcium overload [22–25,31]. Thus, our hypothesis is that carvedilol treatment could improve contractile dysfunction induced by estrogen deficiency.

The goal of this study was to investigate whether carvedilol would prevent ovariectomy-induced myocardial contractile dysfunction. We hypothesized that carvedilol would prevent myocardial contractile dysfunction through a decrease in oxidative stress. Therefore, we analyzed the effects of these treatments on the following: weight gain and hypertrophy induced by ovariectomy; hemodynamic and myocardial contractility; reactive oxygen species production; measurement of plasma ACE activity and expression of key Ca\(^{2+}\)-handling proteins. Our findings provide evidence that carvedilol prevents myocardial contractile dysfunction in ovariectomized female by decreasing the renin angiotensin system activity.

Table 1. Ponderal data from SHAM, Ovariectomized and Ovariectomized plus Carvedilol: BW, body weight (n = 7–9); LV/BW, left ventricle body weight ratio (n = 9–10); Uterus/BW, uterus body weight ratio (n = 8–10); Tibia length (n = 7–10); LV/Tibia, left ventricle tibia ratio (n = 14–19) and papillary muscle weight (n = 7–9).

|                  | SHAM  | OVX   | OVX+CAR |
|------------------|-------|-------|---------|
| BW (g)           | 255±5 | 317±7* | 294±3.6*# |
| LV (g)           | 0.52±0.01 | 0.63±0.02* | 0.54±0.01# |
| LV/BW (mg/g)     | 2±0.02 | 1.94±0.05* | 1.84±0.032* |
| Uterus/BW (mm)   | 2.51±0.25 | 0.9±0.06* | 0.62±0.03* |
| Tibia (mm)       | 38.0±0.43 | 38.6±0.35 | 38±0.18 |
| LV/Tibia (mg/mm) | 14±0.22 | 15.5±0.4* | 14.6±0.3# |
| Papillary Muscle (mg) | 5.35±0.35 | 5.92±0.5 | 6.96±1.3 |

Data are shown as mean ± SEM.

*p<0.05 versus Sham and #p<0.05 versus OVX.

ANOVA one way and Tukey test.

doi:10.1371/journal.pone.0053226.t001

Materials and Methods

Animal Care

The care and use of the laboratory animals were in accordance with National Institutes of Health (NIH) guidelines and were approved by the Institutional Ethics Committee of the Health Science Center of Vitória-EMESCAM. All rats had free access to tap water and food.

Experimental Groups, Surgical Procedures and Treatment

Eight-week-old female Wistar rats were randomly divided into three groups. Rats underwent bilateral ovariectomy as described previously [9,32]. Briefly, rats were anesthetized, and a dorsal midline skin incision was made caudal to the posterior border of the ribs. The posterior abdominal muscle wall was bluntly dissected, the abdominal cavity was opened and the ovary was gently exteriorized and removed. The uterine horn was returned to the abdomen. The skin incision was closed with sterile nylon sutures, and the process was repeated on the other side. The rats were randomly assigned to receive treatment with carvedilol (OVX+CAR, 20 mg/kg in a 0.05% sodium carboxymethylcellulose solution and administered through canula by an oral route, daily) or placebo (OVX), and the last group underwent a SHAM operation and served as normal controls. All treatments lasted for 58 days.

Left ventricle papillary muscle contractility was studied 60 days postsurgery. At the time of sacrifice, the adequacy of the ovariectomy was grossly determined by the absence of ovarian tissue and marked uterine atrophy. We also determined the weight of the entire animal, as well as the weight of the left ventricle and the uterus.

Isometric Tension and Myocardial Contractility

Rats received 500 units of heparin intraperitoneally (i.p.) and were anesthetized 10 minutes later with urethane 1.2 g/kg (Sigma). The hearts were rapidly removed and perfused through the aortic stump as the left ventricle papillary muscles were dissected. Muscle preparations were maintained for isometric tension recording and maintained in 20 mL Krebs–Henseleit solution (in mM: NaCl 118, KCl 4.7, CaCl\(_2\) 1.25, KH\(_2\)PO\(_4\) 1.2, MgSO\(_4\) 1.2, NaHCO\(_3\) 23 and glucose 11) at 30°C and pH = 7.4, which was continuously aerated with 95% O\(_2\) and 5% CO\(_2\). Resting tension was adjusted to produce maximal contractile force (Lmax). The twitch contraction rate was controlled by isolated rectangular pulses (10 to 15 V, 12 ms duration) through a pair of platinum electrodes. The standard stimulation rate was 0.5 Hz (steady-state). Isometric force development was measured with an isometric force transducer (TSD105A, Biopac) and normalized to muscle weight (g/g). Recording started after 30 minutes to permit the muscle to adapt to the new environmental conditions. Myocardial contractility was tested by measuring the positive inotropic response to changes in extracellular calcium (CaCl\(_2\), Merck) concentration (0.62 to 3.75 mM) and by adding isoproterenol (Sigma) concentrations to the bath (10\(^{-8}\) to 10\(^{-5}\) M).

Hemodynamic and Ventricular Compliance Measurements

Animals were anesthetized with a mixture of the ketamine/xylazine (90 mg/kg and 10 mg/kg, respectively). The right carotid artery was isolated, and a polyethylene catheter (PE-50) was inserted and connected to a data acquisition system to measure the hemodynamic parameters. Following an adaptation period of 30 min, arterial pressure acquisition started. The catheter was advanced into the left ventricle, and systolic pressures (LVSP), end-
diastolic pressures (LVEDP), dP/dt +, dP/dt – and heart rate (HR) were continuously monitored for 15 min. To define the passive pressure-volume characteristics of the left ventricle, the heart was arrested in diastole with potassium chloride (1 M) and a double lumen catheter (PE 50 inside PE 200) was inserted 6 mm into the left ventricle via the aorta. The right ventricular free wall was incised to avoid fluid accumulation and variable compressive force on the interventricular septum. The atrioventricular groove was tied, and the ventricle was manually compressed to expel blood and create a negative pressure of −25 mm Hg, which was taken as zero volume. Physiological saline was infused at 0.68 mL/min via one lumen, while the intraventricular pressure was continually recorded through the other lumen over the pressure range of 25 to 30 mmHg. At least three reproducible pressure-volume curves were obtained within 10 minutes of cardiac arrest and well before the onset of rigor mortis. Ventricular volumes at pressures of 0, 2.5, 5, 10, 15, and 30 mmHg were determined from the pressure-volume curve.

The obtained curves were segmented and then separately analyzed. Pressure follows a linear pattern from 0 to 5 mmHg during volume infusion, and the slope is indicative of left ventricular dilatation. For the 5 to 30 mmHg segment, the curve was adjusted to a monoexponential model. Thus, to determine the stiffness constant during the 5–30 mmHg intervals, a logarithmic transformation was performed on the pressure scale to create a linear fit.

Western Blot Analysis

Western blot was performed as previously described [29,33,34]. Proteins from homogenized hearts (50 µg for PLB and 80 µg for the other proteins) were separated by 7.5%, 10% or 15% SDS-PAGE. Proteins were transferred onto nitrocellulose membranes, which were incubated with mouse monoclonal antibodies for SERCA2a (1:1000, Affinity BioReagents, CO, USA), PLB (0.5 µg/ml, Affinity BioReagents, CO, USA), phosphorylated PLB at serine 16 (1:5000, Badrilla, UK), phosphorylated PLB at threonine 17 (1:5000, Badrilla, UK), AT1 receptor (1:1000, Santa Cruz Biotechnology) and AT2 receptor (1:750, Santa Cruz Biotechnology). After washing, the membranes were incubated with anti-mouse (1:5000, Stressgen, Victoria, Canada) or anti-rabbit (1:7000, Stressgen, Victoria, Canada) immunoglobulin antibodies conjugated to horseradish peroxidase. After thorough washing, immunocomplexes were detected using an enhanced horseradish peroxidase/luminal chemiluminescence system (ECL).
Plus, Amersham International, Little Chalfont, UK) and film (Hyperfilm ECL International). Signals on the immunoblot were quantified with the NIH Image V1.56 computer program. Each membrane was reprobed to determine GAPDH expression using a mouse monoclonal antibody (1:5000, Abcam Cambridge, MA, USA).

**In situ Detection of Papillary O$_2^-$ Production**

The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate O$_2^-$ production in situ, as previously described [35]. Dihydroethidium freely permeates cells and is oxidized in the presence of O$_2^-$ to ethidium bromide, which is trapped by intercalation with DNA. Ethidium bromide is excited at 546 nm and emits at 610 nm. Frozen tissue segments were cut into 10-μm-thick sections and placed on glass slides. Serial sections were equilibrated under identical conditions for 30 min at 37°C. Fresh buffer containing DHE (2 μM) was applied topically to each tissue section, covered with a cover slip, incubated for 30 min in a light-protected humidified chamber at 37°C, and then viewed with a fluorescent microscope (Nikon, 200× magnification) using the same imaging settings for all sections. Fluorescence was detected with a 568-nm long-pass filter. For quantification, 8 tissue sections per animal were sampled and averaged for each experimental condition. The mean fluorescence densities in the target region were calculated.

**Measurement of MDA Production**

Plasmatic malondialdehyde (MDA) levels were measured with a modified thiobarbituric acid (TBA) assay [35]. Plasma or powdered heart tissue was mixed with 20% trichloroacetic acid in 0.6 M HCl (1:1 vol/vol), and tubes were incubated on ice for 20 min to precipitate plasma components that present possible interferences. Samples were centrifuged at 1,500xg for 15 min before adding TBA (120 mM in 260 mM Tris, pH = 7) to the supernatant in a proportion of 1:5 (vol/vol), and the mixture was boiled at 97°C for 30 min. Spectrophotometric measurements at 535 nm were performed at 20°C.

**Measurement of Plasma ACE Activity**

Angiotensin converting enzyme activity was measured with a fluorometric method [34]. Briefly, triplicate plasma samples (3 μL) or 75 μg of cardiac homogenized tissue were incubated for 15 minutes at 37°C with 40 μL of assay buffer containing the ACE substrate 5 mM Hip-His-Leu (Sigma). The reaction was stopped by adding 190 μL of 0.35 N HCl. The resulting product (His-Leu) was fluorometrically measured following 10 min incubation with 17 μL of 2% o-phatal-dialdehyde in methanol. Fluorescence measurements were carried out at 37°C in a plate reader (Synergy 2, Biotek) with 350 nm excitation and 520 nm emission filters. The fluorescence plate reader was controlled by the Gen 5 Software. Black 96-well polystyrene microplates (Corning Incorporated, NY, USA) were used. A calibration curve with His-Leu (Sigma) was included in each plate.

**Immunohistochemical Analysis**

Immunohistochemical localization of p22phox was determined in 10-μm sections of frozen papillary muscle using an anti-p22phox (1:50, Santa Cruz Biotechnology) antibody. Briefly, frozen sections were fixed in cold acetone for 3 minutes, followed by pretreatment with 0.3% hydrogen peroxide for 20 minutes to inhibit endoge-
Figure 3. Densitometric analysis of Western blots. SR Ca\textsuperscript{2+}-ATPase (A), phospholamban (PLB), SERCA2a/PLB ratio, AT\textsubscript{1} receptor, phosphorylated phospholamban at Ser\textsuperscript{16} (PLBSer\textsuperscript{16}) and phosphorylated phospholamban at Thr\textsuperscript{17} (PLBThr\textsuperscript{17}) in hearts from SHAM, Ovariectomized (OVX), Ovariectomized plus carvedilol (OVX+CAR) rats. The values are expressed as the means ± S.E.M * p<0.05 vs. SHAM rats. # p<0.05 vs. OVX rats using one-way ANOVA and Tukey post hoc test. Number of animals in indicated in parenthesis. Representative blots are shown. doi:10.1371/journal.pone.0053226.g003
nous peroxidase activity. Subsequently, sections were blocked with 5% horse serum for 60 min and incubated with the primary antibody overnight at 4°C. After rinsing with PBS, the sections were incubated for 30 min with a biotinylated secondary antibody, followed by incubation with avidin-biotinylated horseradish peroxidase complex (Vectastain ABC, Vector). Serial sections treated with nonimmune IgG did not show any staining. Peroxidase staining was detected using the DAB detection system (Vector Laboratories).

Cardiac Interstitial Collagen Quantification

Tissue samples from left and right ventricles were dehydrated, embedded in paraffin and cut in sections of 5 μm thickness. These sections were stained with picrosirius red staining (Aldrich Chemical Company). Interstitial collagen quantifications in the left ventricles were performed using an image analysis system (BEL Engineering, Top Light B2, Italy). The area of interstitial fibrosis was identified after excluding the vessel area and scar area from the region of interest and determined as the ratio of interstitial collagen deposit to the total remaining tissue area from each ventricle. For each sample, 10 to 15 fields were analyzed with a 40× objective lens under transmitted light. All procedures were performed in samples obtained from middle transversal segments of the heart.

Table 2. Changes in systolic (SBP) and diastolic blood pressure (DBP), heart rate (HR), left (LVSP) ventricle systolic pressure, left ventricle diastolic pressure (LVEDP), and the positive (dP/dt max) and negative first time derivatives (dP/dt min) from SHAM, Ovariectomized (OVX) and Ovariectomized plus Carvedilol (OVX+CAR).

|               | SHAM | OVX | OVX+CAR |
|---------------|------|-----|---------|
| SBP (mmHg)    | 109±3.8 | 106±3.9 | 113±5.6  |
| DBP (mmHg)    | 81±3.1  | 80±3  | 84±4.2   |
| HR (bpm)      | 193±6   | 186±5  | 188±10   |
| LVSP (mmHg)   | 109±3   | 109±3.9 | 121±5.1  |
| LVEDP (mmHg)  | 7.6±0.7 | 7.8±0.7 | 8.3±1    |
| dP/dt max LV  | 4354±118 | 4334±145 | 4508±123 |
| dP/dt min LV  | 3430±145 | 3388±204 | 3474±205 |

Data are shown as mean ± SEM. N=6-9. doi:10.1371/journal.pone.0053226.t002

Statistical Analysis

All values are expressed as the means ± SEM. Differences among groups were analyzed using one- or two-way ANOVA, repeated measures followed by the Tukey post hoc test for multiple comparisons. A p-value <0.05 was considered significant. For protein expression, the data are expressed as the ratio between the protein of interest and GAPDH.

Drugs and Chemicals

All chemicals, unless otherwise specified, were purchased from Sigma Chemical (St. Louis, MO) or Merck (Germany).

Results

Body, Heart and Uterus Weight

The body weights of ovariectomized rats were significantly greater than those of SHAM rats. Carvedilol treatment reduced weight gain after ovariectomy (Table 1). Ovariectomy and carvedilol treatment decreased left ventricle weight to body weight ratio explained by the weight gain in both groups. The left ventricle weight was found higher in the OVX group when compared to SHAM and carvedilol treatment prevented this increase (SHAM: 0.56±0.01, OVX: 0.63±0.02* and OVX+CAR: 0.54±0.01*). When we evaluated the left ventricle weight to tibia length ratio, rats in the OVX group exhibited a significantly higher ratio compared to SHAM, and carvedilol treatment

Figure 4. Immunohistochemistry of p22phox in papillary muscle. Photomicrographs of short-axis cross-sections of papillary muscle from representative animals in the SHAM, OVX, OVX+CAR groups that were immunostained for p22phox with DAB (brown). Regions of interest are shown at higher magnification (200X). Strong p22phox immunoreactivity was noted in the OVX group. In carvedilol rats, p22phox immunoreactivity was dramatically decreased in the papillary muscle.

doi:10.1371/journal.pone.0053226.g004

Figure 5. Left ventricular collagen content. The data is expressed as the mean ± S.E.M. * p<0.05 vs. SHAM rats. # p<0.05 vs. OVX rats using one-way ANOVA and Tukey post hoc test. Number of animals in indicated in parenthesis.

doi:10.1371/journal.pone.0053226.g005
restored this ratio to the same level as the SHAM group (Table 1). The deficiency of estrogen in OVX and OVX+CAR rats induced a significant decrease in uterine weight compared to SHAM controls. The tibia length and papillary muscle weight did not differ among groups (Table 1).

**Isometric Contractile Response to Calcium**

As expected, increases in extracellular calcium concentration resulted in a positive inotropic response (Figure 1). We found a difference in the inotropic response to calcium between the OVX and SHAM groups for all concentrations studied (Figure 1A); the OVX group response is approximately 50% less compared to the SHAM rats. Interestingly, carvedilol treatment restored the reduction in the inotropic response to extracellular Ca^{2+} (Figure 1A).

**Isometric Contractile Response to β-adrenergic Receptor Stimulation**

Dose-response curves were measured for isoproterenol, a nonspecific β-adrenergic agonist (Figure 1B). β-adrenergic receptor stimulation in the heart increases contractility and accelerates relaxation by activating the adenylyl cyclase/cAMP/protein kinase pathway. As expected, isoproterenol promoted a positive inotropic effect in all groups studied. However, this response was reduced in the OVX group compared to SHAM controls by approximately 50% (Figure 1B). Carvedilol treatment restored the inotropic response to isoproterenol (Figure 1B).

**Plasmatic ACE Activity, Papillary Superoxide Anion Production and Plasmatic MDA Levels**

After 8 weeks, plasma ACE activity was 2.8-fold greater in the OVX compared to SHAM group. Carvedilol treatment decreased ACE activity as compared to OVX group (Figure 1C). Cardiac ACE activity was not different in the left ventricle (SHAM: 39±3.2; OVX: 37±1.3; OVX+CAR: 35±2.2 nmol-His-Leu/mL/min).

Basal superoxide anion production was 4-fold higher in papillary segments from OVX rats than in SHAM rats. Carvedilol treatment prevented the increase in superoxide production in papillary segments from OVX+CAR rats (Figure 2).

Plasmatic MDA levels did not differ between SHAM and OVX groups. However, the carvedilol group exhibited a lower MDA level compared to the SHAM group (Figure 1D). Cardiac MDA levels did not differ among groups (SHAM: 0.08±0.04; OVX: 0.13±0.05; OVX+CAR: 0.08±0.02).

**Western Blot Analysis**

Alterations in cardiac mechanical properties and intracellular calcium handling are dependent on SERCA2a and PLB. In this study, we examined the role of these proteins in the altered myocardial contractility seen in rats 60 days after ovariectomy. As shown in Figure 3, SERCA2a protein expression is approximately 50% lower in the OVX group (Figure 3A), and PLB protein expression is increased (Figure 3B). Carvedilol treatment effectively prevented the change in SERCA2a levels but did not prevent the increase in PLB (Figure 3A and 3B). Figure 3 also demonstrates that the PLB levels in the OVX group were 1.7-fold higher than the SHAM group. The ratio of SERCA2a to PLB protein levels was significantly reduced (approximately 72%) in ovarian sex hormone-deficient hearts (Figure 3C) and improved by carvedilol treatment (Figure 3C). To examine the modulating effect of PLB on the responsiveness of SERCA2a to Ca^{2+} in ovariectomized hearts, the levels of PLB phosphorylated at either the Ser^{16} or Thr^{17} was analyzed. We did not find any difference among the groups in the content of the phosphorylated form of PLB at Ser^{16} (Figure 3E), but we did find an increase in the content of the phosphorylated form at Thr^{17} in the OVX group compared to SHAM group. Carvedilol treatment restored these changes (Figure 3F).

Furthermore, we analyzed the expression of the AT1 and AT2 receptors and we found an increase in AT1 receptor protein expression in the carvedilol-treated group although no was found among the other groups (Figure 3D). AT2 protein expression did not differ among the groups (data not shown).

**Immunohistochemical Analysis**

Immunohistochemistry for p22phox was performed in serial sections to define the spatial distribution of p22phox protein expression in papillary muscle. As illustrated in Figure 4, immunoreactivity for p22phox was readily detected in OVX hearts. Carvedilol treatment diminished ovariectomy-induced increase in protein expression in papillary muscle.

**Hemodynamic, Pressure-Volume Data and Collagen Content**

Passive pressure-volume curve was analyzed in 2 segments: the first linear segment representing the dilatation constant, and an exponential segment indicating left ventricular stiffness. Ventricular volume or ventricular stiffness measured in the potassium-arrested heart did not differ among groups. Left ventricular dilatation or ventricular stiffness was similar among all groups, showing that carvedilol treatment did not change these parameters (data not shown). We also did not find any change in the arterial or ventricular pressure (Table 2).

However, fibrosis in the spare myocardium, measured as the percentage of the area occupied by interstitial collagen, was significantly higher in the OVX group when compared to SHAM animals. Moreover, carvedilol treatment restored this increase observed in the OVX group (Figure 5).

**Discussion**

Our study demonstrates that carvedilol prevented cardiac contractile dysfunction and oxidative stress after ovariectomy. This response was associated with changes in expression levels of one key protein involved in calcium handling, SERCA2a. Carvedilol normalized ovariectomy-induced contractile dysfunction, restored the SERCA2a levels and diminished reactive oxygen species formation. Furthermore, carvedilol attenuated the increase in p22phox expression and affected the increase in ACE activity in the OVX group.

Clinical trials have shown that carvedilol improves heart function, morbidity, mortality rates of chronic heart failure patients and it has also been proven to be more effective than other beta blocker such as metoprolol [36–39]. Carvedilol has high antioxidant activity compared to any other beta blocker [22]. In vitro and in vivo studies showed that carvedilol prevents lipid peroxidation in myocardial cell membranes initiated by ROS [39]. Our results also show that carvedilol decreased lipid peroxidation even though ovariectomy did not increase plasmatic MDA levels.

Estrogen down-regulates most of the components of the renin angiotensin system, including ACE and AT1 receptor [4,19,40,41]; therefore, estrogen deficiency leads to upregulation of AT1 and its affinity for angiotensin II [42]. Overexpression of angiotensin II in the heart induces cardiomyocyte remodeling such as hypertrophy, increases collagen synthesis and decreases SERCA2a expression, leading to contractile dysfunction [43,44].
Angiotensin II most likely affects negatively excitation-contraction coupling in the myocardium by increasing superoxide production [45]. Prolonged exposure to angiotensin II activates the Ca2+/calmodulin-dependent protein kinase (CaM/K) II and PLBThr17 by increasing reactive oxygen species, which leads to cell death [46].

The main source of reactive oxygen species activated by angiotensin II is the enzyme NADPH oxidase, which is associated with a smaller protein called p22phox [15]. Female animals have reduced levels of p22phox and superoxide anion production as well [47]. This enzyme is related to cardiac remodeling and vascular dysfunction in myocardial infarction, hypertension and aging [15,47–51]. Our results showed that carvedilol decreased the expression of p22phox, the NADPH oxidase subunit as well as superoxide anion production induced by ovariectomy. Carvedilol treatment also decreased ACE activity and increased AT1 receptor protein expression, in agreement with other studies, our results suggest that carvedilol down-regulates the renin angiotensin system [26,52–54].

Reactive oxygen species are capable of influencing calcium homeostasis and cellular signaling via posttranslational modifications, such as S-glutathionylation, which inhibits calcium-induced calcium release in rat cardiomyocytes [55]. Reactive oxygen species can modulate calcium handling proteins [56], such as SERCA2a and L-type calcium channels, thereby contributing to slowed calcium transients [57–61].

Koitaabashi et al [23] showed that carvedilol blocks oxidative stress-mediated downregulation of SERCA2a and suggests that carvedilol upregulates SERCA2a gene transcription by its antioxidant property. Oxidative stress may have contributed to the myocardial contractile dysfunction observed in OVX rats. Estrogen deficiency has been related to myocardial contractile dysfunction. In agreement with other studies, our results suggest that estrogen deprivation-induced myocardial contractile dysfunction is linked to alterations in SERCA2a and PLB expression [1,9,10]. Phospholamban regulates SERCA2a activity by modulating calcium uptake into the sarcoplasmic reticulum and muscle relaxation [9,27–29]. Based on transgenic and gene-targeted mouse model studies, alterations to the PLB to SERCA2a ratio has been suggested to be a major regulator of cardiac contractility [62–64].

In vivo studies using transgenic mice that overexpress cardiac specific PLB suggested that the “functional stoichiometry” of PLB/SERCA2a is less than 1:1 in native cardiac sarcoplasmic reticulum membranes [62]. Here, we show that this ratio is threefold higher in the OVX group compared to the sham group. Phospholamban is a repressor of left ventricular basal contractile parameters, and alterations in the levels of phospholamban would be expected to result in alterations in myocardial contractility. Two-fold higher PLB protein levels in transgenic mice compared to wild type resulted in decreased Ca2+-ATPase affinity for Ca2+, which was associated with decreased contractility and Ca2+ transport in cardiomyocytes [62]. Carvedilol treatment did not change phospholamban levels, however, it increased SERCA2a levels, thereby improving PLB/SERCA ratio.

In summary, our data indicate that treatment with carvedilol prevented the weight gain, myocardial contractile dysfunction and slight hypertrophy induced by ovariectomy. Moreover, this myocardial contractile dysfunction appeared to be dependent on superoxide anion production, which has detrimental effects on SERCA2a levels. Taken together, our findings provide evidence that carvedilol prevented myocardial contractile dysfunction in ovariectomized female rats by decreasing the renin angiotensin system activity.

Author Contributions
Conceived and designed the experiments: RFRJF AAF IS. Performed the experiments: RFRJ FFP BMMP LF FLMLF JF. Analyzed the data: RFRJ FFP BMMP LF. Wrote the paper: RFRJ AAF DVV IS.

References
1. Bupha-Intr T, Wanapatpermool J (2006) Regulatory role of ovarian sex hormones in calcium uptake activity of cardiac sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol 291: H1101–H1108. 00660-2005 [pii];10.1152/ajpheart.00660-2005 [doi].
2. Lloyd-Jones D, Adams RJ, Carnethon M, Dai S, et al. (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121: e6–e215. CIRCULATIONAHA.109.192667 [pii];10.1161/CIRCULATIONAHA.109.192667 [doi].
3. Farrell SR, Ross JF, Howlett SE (2010) Sex differences in mechanisms of cardiac excitation-contraction coupling in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 299: H136–H145. aiph00299.2010 [pii];10.1152/ajpheart.00299.2010 [doi].
4. Sumino H, Ichikawa S, Ohyama Y, Nakamura T, Kanda T, et al. (2003) Effects of hormone replacement therapy on serum angiotensin-converting enzyme genotype. Hypertens Res 26: 53–58.
5. Stanley WC, Dubowski ER, Riehle RF Jr, O’Connell KA (2012) Dietary fat and heart failure: moving from lipotoxicity to lipoprotection. Circ Res 110: 764–776. 1105764AHC [pii];10.1161/CIRCRESAHA.111.125104 [doi].
6. Koitaabashi et al (2012) Sex differences in mechanisms of cardiac excitation-contraction coupling in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 299: H136–H145. aiph00299.2010 [pii];10.1152/ajpheart.00299.2010 [doi].
7. Morpurgo E (2011) Estrogen signaling and cardiovascular disease. Circ Res 109: 607–606. 109607AHC [pii];10.1161/CIRCRESAHA.110.236687 [doi].
8. Shlipsak MG, Chaput LA, Vittinghoff E, Lau F, Bittner V, et al. (2003) Lipid changes on hormone therapy and coronary heart disease events in the Heart and Estrogen/progestin Replacement Study. HERS. Am Heart J 146: 670–675. 10135217 [pii];10.1016/S0002-9343(02)01425-7 [doi].
9. Pajgel AS, Riehle RF Jr, Fernandes AA, Taraguta GP, Vasallo DV, et al. (2011) Myocardial contractility is preserved early but reduced late after ovariectomy in young female rats. Reprod Biol Endocrinol 9: 54. 10135217–6705-9-54 [pii];10.1186/1477-7827-9-54 [doi].
10. Bupha-Intr T, Laosiripana J, Wanapatpermool J (2009) Moderate intensity of regular exercise improves cardiac SR Ca2+/ATPase activity in ovariectomized rats. J Appl Physiol 107: 1105–1112. 00407-2009 [pii];10.1152/japplphysiol.00407-2009 [doi].
11. Pines A, Fisman EZ, Levo Y, Drovy Y, Ben-Ari E, et al. (1993) Menopause-induced changes in left ventricular wall thickness. Am J Cardio 72: 240–241.
12. Plevcic GM, Brljic T (1994) The effect of oestradiol and progesterone replacement therapy on systolic flow velocity in healthy postmenopausal women. Maturitas 20: 37–44.
13. Schuett J, Mallhora A, Schaffe TF, Capasso J (1987) Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 61: 12–19.
14. Wanapatpermool J, Reiser JR (1999) Differential effects of ovariectomy on calcium activation of cardiac and soleus myofibrils. Am J Physiol 277: H667–H673.
15. Akki A, Zhang M, Murdoch C, Brewer A, Shah AM (2009) NADPH oxidase signaling and cardiac myocyte function. J Mol Cell Cardiol 47: 15–22. 00022-2828(09)00052-7 [pii];10.1016/j.yjmcc.2009.04.004 [doi].
16. Ribeiro RF Jr, Pavan BM, Potratz FF, Forum J, Simoes MR, et al. (2012) Myocardial Contractile Dysfunction Induced by Ovariectomy Requires AT1Receptor Activation in Female Rats. Cell Physiol Biochem 30: 1–12. 000339041 [pii];10.1159/000339041 [doi].
17. Prouse AJ, Ahmed AI, Crook D, Fogelman I, Rymer JM, et al. (1995) Hormone replacement therapy and serum angiotensin-converting-enzyme activity in postmenopausal women. Circulation 92: 89–90. 0041463763/95/291114·1 [pii].
18. Fischer M, Baeder A, Schunkert H (2002) Renin angiotensin system and gender differences in the cardiovascular system. Cardiovasc Res 53: 672–677. S0005686301004795 [pii].
19. Gallagher PJ, Li P, Lenhart JR, Chappell MC, Brosnihan KB (1999) Estrogen regulation of angiotensin-converting enzyme mRNA. Hypertension 33: 323–328.
20. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, et al. (2005) Myocardial Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46: 426–432.
21. Zima AV, Blatter LA (2006) Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 71: 310–321. S0008-6363(06)00081-2 [pii];10.1159/0003280002.0019 [doi].
22. Dandona P, Ghanim H, Brooks DP (2007) Antioxidant activity of carvoldiol in cardiovascular disease. J Hypertens 25: 731–741. 10.1097/HJH.0b013e3280127948 [doi].

23. Koitabashi N, Arai M, Tomaru K, Takizawa T, Watanabe A, et al. (2005) Carvoldiol effectively blocks oxidative stress-mediated downregulation of sarco(endo)plasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem Biophys Res Commun 328: 116–124. S0006-291X(04)00296-0 [pii].

24. Ribeiro RF Jr, Fernandes AA, Metra M, Felker GM, Fonseca JC, Rechera LR, et al. (2008) Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. J Mol Cell Cardiol 45: 249–259. 10.1016/j.yjmcc.2008.05.011 [doi].

25. Yue TL, Ma XL, Gu JL, Ruffolo RR Jr, Feuerstein GZ (1998) Carvoldiol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart. Eur J Pharmacol 354: 61–63. S0166-2236(98)00253-5 [pii].

26. Barki-Harrington L, Luttrell LM, Rockman HA (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor cross-talk in vivo. Circulation 108: 1611–1618. 10.1161/01.CIR.0000092166.30360.76 [pii].

27. Simmerman HK, Jones LR (1998) Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol Rev 78: 921–947.

28. Britton AG, Kranias EG (2000) Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32: 2131–2139. 10.1016/s0022-5191(00)00276-1 [pii].

29. Ribeiro RF Jr, Fernandes AA, Metra M, Batista PR, Simon FD, et al. (2010) Soybean oil increases SERCA2a expression and left ventricular contractility in rats without change in arterial blood pressure. Lipo J Health Nutr 35: 93, 1476–511X-9-53 [pii].

30. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY (2005) Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 128: 1812–1821. 128/3/1812 [pii].

31. Gomes A, Costa D, Lima JL, Fernandes E (2006) Antioxidant activity of beta-blockers: an effect mediated by scavenging reactive oxygen and nitrogen species? Biochem Med 14: 456–457. S0906-8696(06)00174-X [pii].

32. Giuberti K, Pereira RB, Bianchi PR, Paigel AS, Vassallo DV, et al. (2007) Acute lead exposure increases arterial pressure: role of the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. J Clin Hypertens 10: 919–925. 10.1111/j.1751-7517.2007.00337.x [pii].

33. Simoes MR, Ribeiro RF Jr, Vescovi MV, de Jesus HC, Padilha AS, et al. (2011) Low mercury concentrations cause oxidative stress and endothelial dysfunction in the DOCA-salt model of hypertension in rats. Peptides 30: 2309–2315. S0196-9781(09)00363-5 [pii].

34. Brittsan AG, Kranias EG (2000) Phospholamban and cardiac contractile function. J Mol Cell Cardiol 32: 2131–2139. 10.1016/s0022-5191(00)00276-1 [pii].

35. Barki-Harrington L, Luttrell LM, Rockman HA (2003) Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor cross-talk in vivo. Circulation 108: 1611–1618. 10.1161/01.CIR.0000092166.30360.76 [pii].

36. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, et al. (2001) Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, REDUCTIVE and CYCLOPS studies. J Am Coll Cardiol 37: 1354–1364.

37. Remme WJ, Torp-Pedersen C, Cleland JG, Poole-Wilson PA, Metra M, et al. (2001) Carvedilol and Myocardial Contractile Dysfunction: Results from the Carvedilol and Metoprolol European Trial in Heart Failure (CAMELOT). J Am Coll Cardiol 37: 1354–1364.

38. Simon SJ, Sealey JE, Mann SJ, Bragat A, Marion R, et al. (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 12: 451–459. S0167-5202(00)00903-9 [pii].

39. Buhler FR, Lazzar LH, Heer CL, Vaughan ED Jr, Brunner HR (1972) Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 267: 1209–1214. 10.1056/NEJM197212072672401 [pii].

40. Michelakis EM, McAllister RG (1972) The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 34: 386–394.

41. Cherednichenko G, Zima AV, Feng W, Schafer S, Blatter LA, et al. (2004) NADH oxidase activity of rat cardiac sarcoplasmic reticulum regulates calcium-induced calcium release. Circ Res 94: 478–486. 10.1161/01.RES.0000145334.51572.7C [pii].

42. Zhai L, Shao Y, Huang Y, Yao T, Lu LM (2007) 17beta-estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol 563: 169–176. 10.1016/j.ejphar.2007.05.047 [pii].

43. Domenighetti AA, Wang Q, Egger M, Richards SM, Podzrazini T, et al. (2005) Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension 46: 432–436. 10.1161/HYPERTENSIONAHA.104.005337 [pii].

44. Zhou L, Shao Y, Huang Y, Yao T, Lu LM (2007) 17beta-estradiol inhibits angiotensin II-induced collagen synthesis of cultured rat cardiac fibroblasts via modulating angiotensin II receptors. Eur J Pharmacol 563: 169–176. 10.1016/j.ejphar.2007.05.047 [pii].

45. Palomeque J, Rueda OV, Saipa L, Valverde CA, Perez S, et al. (2008) Angiotensin II-induced negative inotropy in rat ventricular myocytes: role of reactive oxygen species and MAPK. Am J Physiol Heart Circ Physiol 296: H16–H16.